Edition:
United States

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

20.31USD
26 May 2017
Change (% chg)

$0.10 (+0.49%)
Prev Close
$20.21
Open
$20.22
Day's High
$20.65
Day's Low
$20.13
Volume
195,554
Avg. Vol
508,422
52-wk High
$35.32
52-wk Low
$15.15

Latest Key Developments (Source: Significant Developments)

Myriad Genetics reports Q3 adj earnings per share $0.27
Tuesday, 2 May 2017 04:05pm EDT 

May 2 (Reuters) - Myriad Genetics Inc :Myriad Genetics reports fiscal third-quarter 2017 financial results.Q3 adjusted earnings per share $0.27.Q3 gaap earnings per share $0.06.Q3 revenue $196.9 million versus i/b/e/s view $189.1 million.Q3 earnings per share view $0.23 -- Thomson Reuters I/B/E/S.Myriad Genetics Inc sees fiscal year 2017 revenue in the range of $763 million to $765 million.Myriad Genetics Inc sees 2017 gaap earnings per share $0.23-$0.25.Myriad Genetics Inc sees 2017 non-gaap earnings per share $1.01-$1.03.Fy2017 earnings per share view $0.99, revenue view $751.5 million -- Thomson Reuters I/B/E/S.  Full Article

Myriad Genetics, Clovis Oncology sign agreement for use of FDA-approved BRACAnalysis CDx test
Thursday, 27 Apr 2017 07:05am EDT 

April 27 (Reuters) - Myriad Genetics Inc ::Myriad Genetics and Clovis oncology sign agreement for use of FDA-approved BRACAnalysis CDX® test to identify patients with Germline BRCA mutations for Rubraca® (rucaparib) treatment.Says financial terms of deal were not disclosed..Myriad genetics inc- under deal,myriad will submit supplementary premarket approval application for bracanalysis cdx to include rubraca.  Full Article

Myriad Genetics, Beigene sign agreement
Thursday, 6 Apr 2017 07:05am EDT 

Myriad Genetics Inc : Myriad Genetics and Beigene sign agreement to develop companion diagnostics for use with Beigene's novel parp inhibitor, BGB-290 . Myriad Genetics Inc - specific terms of deal were not disclosed. .Myriad Genetics-under deal Beigene to use co's mychoice HRD, bracanalysis CDX companion diagnostic tests to support clinical development of BGB-290.  Full Article

Myriad Genetics publishes study evaluating its myPath melanoma test
Wednesday, 5 Apr 2017 07:05am EDT 

Myriad Genetics Inc - : Myriad Genetics -published third clinical validation study and second clinical utility study for its mypath melanoma test . Myriad Genetics Inc says will submit reimbursement dossier to medicare and private insurers three months earlier than expected .Myriad Genetics-3rd clinical validation study shows mypath melanoma test had overall diagnostic accuracy of 95 percent to differentiate melanoma from benign lesions.  Full Article

Myriad Genetics director Henderson buys 6,000 shares of co's common stock on Feb 22-23
Thursday, 23 Feb 2017 11:27am EST 

Myriad Genetics Inc :Myriad Genetics Inc director John Henderson reports purchase of 6,000 shares of co's common stock on Feb 22-23 - SEC filing.  Full Article

Myriad Genetics reports fiscal Q2 2017 financial results
Tuesday, 7 Feb 2017 04:05pm EST 

Myriad Genetics Inc : Myriad Genetics reports fiscal second-quarter 2017 financial results . Q2 adjusted earnings per share $0.26 . Q2 GAAP earnings per share $0.09 . Q2 revenue $196.5 million versus I/B/E/S view $189.7 million . Q2 earnings per share view $0.24 -- Thomson Reuters I/B/E/S . Myriad Genetics Inc sees FY 2017 GAAP revenue $745-$755 million . Myriad Genetics Inc sees FY 2017 GAAP diluted earnings per share $0.31-$0.36 . Myriad Genetics Inc sees FY 2017 adjusted earnings per share $1.00-$1.05 . Myriad Genetics Inc sees Q3 revenue $188-$190 million . Myriad Genetics Inc sees Q3 GAAP diluted earnings per share $0.08-$0.10 . Myriad Genetics Inc sees Q3 adjusted earnings per share $0.23-$0.25 . Q3 earnings per share view $0.25, revenue view $190.2 million -- Thomson Reuters I/B/E/S .FY2017 earnings per share view $0.98, revenue view $751.8 million -- Thomson Reuters I/B/E/S.  Full Article

Myriad Genetics says entered into credit agreement for $300 mln on Dec.23-SEC filing
Wednesday, 28 Dec 2016 11:51am EST 

Myriad Genetics Inc : On Dec. 23, 2016, entered into a credit agreement - SEC filing . Senior secured revolving credit facility in an aggregate principal amount of up to $300 mln-SEC filing .Credit facility matures on Dec. 23, 2021.  Full Article

Myriad RBM announces agreement with Sanofi
Tuesday, 25 Oct 2016 07:05am EDT 

Myriad Genetics Inc : Announces an agreement with Sanofi to measure predictive cardiovascular biomarkers in patients with diabetes . Financial terms of deal were not disclosed .Under agreement, Sanofi will provide approximately 5,300 serum samples from elixa trial.  Full Article

Myriad Genetics to enter into a credit agreement
Thursday, 1 Sep 2016 04:25pm EDT 

Myriad Genetics Inc : Says on August 31 co entered into a credit agreement . Pursuant to credit agreement, Myriad borrowed term loans in an aggregate principal amount of $200.0 million .Proceeds of term loans used to finance acquisition of Assurex ,refinance certain existing indebtedness of Assurex and its units.  Full Article

Myriad Genetics reports Q4 earnings per share $0.32
Tuesday, 9 Aug 2016 04:05pm EDT 

Myriad Genetics : Reports fiscal fourth-quarter 2016 financial results . Q4 earnings per share $0.32 . Q4 earnings per share view $0.37 -- Thomson Reuters I/B/E/S . Q4 adjusted earnings per share $0.36 .Q4 revenue $186.5 million versus I/B/E/S view $187.9 million.  Full Article

More From Around the Web

BRIEF-Myriad Genetics announced new data "demonstrating utility" of prolaris test

* Myriad Genetics - announced new data "demonstrating utility" of prolaris test to predict 10-year risk of metastases in men treated for prostate cancer Source text for Eikon: Further company coverage: